Gindin. J1, Amselem. S2.
1Geriatric Department and Geriatric Institute of Education and Research, Kaplan-Herzfeld Medical Center
and 2Pharmos Ltd., Rehovot, Israel.
The objective of this study was to compare the oral bioavailability of Coenzyme Q10 among geriatric patients after administration of generic CoQ10 or Emulsone™-CoQ10 - a formulation based on a new patented technology, that aims to improve the absorption of food supplements and biopharmaceuticals.
The selected population was hospitalized, geriatric patients undergoing continuous treatment with various medications.
The results of this study demonstrate the effectiveness of Emulsome™-CoQ10 with significant enhanced oral bioavailability of CoQ10 in comparison to a generic CoQ10.
CoQ10 deficiency has been found in patients with diabetes mellitus, severe ischemic heart disease and in patients treated with cholesterol lowering “statins drugs”. Supplementary CoQ10 therapy has been shown to be beneficial in treating congestive heart failure, dyslipidemia, complications of diabetes and Parkinson’s disease. Improved oral absorption of Ultrasome™- CoQ10 is particularly important in elderly patients diagnosed with chronic and debilitating conditions known to have poor gastrointestinal absorption.
